Bausch + Lomb Corporation - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
BLCO New York 3850 www.bausch.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bausch + Lomb Corporation

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 - Jan 22nd, 2025 12:00 pm
This Bausch + Lomb Insider Increased Their Holding In The Last Year - Jan 21st, 2025 3:39 pm
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences - Jan 13th, 2025 12:00 pm
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union - Jan 13th, 2025 11:00 am
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20? - Jan 12th, 2025 2:30 pm
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual "Faces of Glaucoma" Campaign and Fundraising Challenge - Jan 7th, 2025 12:00 pm
Bausch + Lomb price target lowered to $22 from $25 at Evercore ISI - Jan 3rd, 2025 11:46 am
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Jan 2nd, 2025 12:00 pm
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - Dec 13th, 2024 3:45 pm
Bausch + Lomb Responds to Rumors of a Potential Sale - Dec 12th, 2024 12:00 pm
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities - Dec 11th, 2024 11:59 am
Bausch & Lomb Corporation (BLCO)-A Bull Case Theory - Nov 22nd, 2024 7:31 pm
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs - Nov 14th, 2024 12:00 pm
Bausch + Lomb Third Quarter 2024 Earnings: Beats Expectations - Nov 1st, 2024 3:27 pm
Bausch & Lomb Corp (BLCO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Oct 31st, 2024 7:06 am
Bausch + Lomb Announces Third-Quarter 2024 Results - Oct 30th, 2024 11:00 am
Bausch + Lomb price target raised to $23 from $20 at RBC Capital - Oct 23rd, 2024 1:45 pm
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens - Oct 14th, 2024 11:00 am
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 - Oct 9th, 2024 12:00 pm
Bausch + Lomb price target raised to $19 from $17 at Evercore ISI - Oct 2nd, 2024 12:40 pm